Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Tiragratide vs Mazdutide
An educational, source-based comparison of Tiragratide and Mazdutide — how each peptide works, what it's researched for, and what to know before going deeper.
Investigational triple hormone receptor agonist for metabolic disease.
An investigational peptide agonist targeting GLP-1, GIP, and glucagon receptors. Similar mechanism to retatrutide, designed to maximize weight loss while preserving lean mass through multi-pathway metabolic modulation.
- Obesity and metabolic syndrome
- Type 2 diabetes glycemic control
- NAFLD and liver fat reduction
- • Investigational; not yet FDA-approved.
- • Requires physician oversight in clinical trials.
A dual agonist of GLP-1 and glucagon receptors, similar to survodutide. The glucagon component increases energy expenditure while GLP-1 suppresses appetite and improves glycemic control.
- Chronic weight management
- Type 2 diabetes
- MASH / NAFLD
- • Investigational; not FDA-approved.
- • Glucagon agonism may affect heart rate and blood pressure.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Tiragratide | Tiragratide Phase 2 trial in obesity | Diabetes Care | 2025 | Demonstrated significant weight reduction with favorable GI tolerability profile. |
| Mazdutide | Mazdutide for obesity: Phase 2 results | The Lancet Diabetes & Endocrinology | 2024 | Achieved ~15% mean weight loss at 48 weeks with manageable side effects. |
Side-effect & safety grid
- Investigational; not yet FDA-approved.
- Requires physician oversight in clinical trials.
- Investigational; not FDA-approved.
- Glucagon agonism may affect heart rate and blood pressure.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Tiragratide vs Mazdutide — Key differences
- Class: Tiragratide is classified as Metabolic · Incretin, while Mazdutide is Metabolic · Incretin.
- Primary research focus: Tiragratide — obesity and metabolic syndrome; Mazdutide — chronic weight management.
- Tag: Metabolic vs Weight loss.